Market Cap 1.03B
Revenue (ttm) 8.55M
Net Income (ttm) -182.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,138.25%
Debt to Equity Ratio 0.00
Volume 317,100
Avg Vol 434,322
Day's Range N/A - N/A
Shares Out 21.05M
Stochastic %K 80%
Beta 2.62
Analysts Strong Sell
Price Target $103.33

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-ty...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 300 8460
Address:
99 High Street, 30th Floor, Boston, United States
Quantumup
Quantumup Aug. 20 at 2:03 PM
H.C. Wainwright reiterated $DRUG Buy/$85. LBPH - $HLUBF/ $HLBBF $PRAX $JAZZ UCBJY UCBJF SNDX AVXL PHVS H.C. Wainwright said in its note:
0 · Reply
R84877P
R84877P Aug. 11 at 1:43 PM
0 · Reply
Quantumup
Quantumup Aug. 11 at 12:51 PM
Piper Sandler reitd $PRAX OW/$270. Following positive Ph2 RADIANT FOS data, we hosted $PRAX for a fireside chat and learned new details reaffirming vormatrigine's competitive and potentially transformational product profile. Specifically, mgmt highlighted vormatrigine showed a consistent PK profile in refractory FOS (vs HVs) with a linear response across AUC and Cmax effectively derisking 40 mg may drive deeper efficacy. Additionally, mgmt specified most discontinuations occurred during weeks 1-3 of RADIANT where blinded Ph2/3 POWER1 data is showing substantially fewer discontinuations thus far. In that vein, mgmt detailed POWER1 is "at-least" 80% powered to show a placebo-adjusted 30% reduction in median seizure frequency where competitor data suggests consistent response across open-label and randomized placebo-controlled trials. Hence, we came away from the fireside chat even more confident in vormatrigine's value proposition with full RADIANT data and POWER1 completion 4Q25. $XENE $BHVN
1 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 10:30 AM
HC Wainwright & Co. updates rating for Praxis Precision Medicine ( $PRAX ) to Buy, target set at 105 → 115.
0 · Reply
LewisDaKat
LewisDaKat Aug. 5 at 12:55 AM
News out Praxis Precision Medicines to Participate in Upcoming Fireside Chat https://marketwirenews.com/news-releases/praxis-precision-medicines-to-participate-in-upcomin-5410024713418557.html $PRAX
0 · Reply
dgbio
dgbio Aug. 4 at 7:36 PM
$PRAX 22% of the patients with 100% seizure reduction is a very good result. Epilepsy is a diverse disease, with diverse treatments. You can't expect to treat everyone with a single drug. Novel treatments reach on average only about $300M in sales in the US market. If vormatrigine can treat 20% of the resistant FOS epilepsy patients it's more than $1 billion in the U.S. sales.
0 · Reply
R84877P
R84877P Aug. 4 at 5:05 PM
$PRAX Looking good
0 · Reply
Smellmahass
Smellmahass Aug. 4 at 1:39 PM
$PRAX News isnt good enough. I expect this to drop below 40 today.
3 · Reply
stingrae
stingrae Aug. 4 at 1:28 PM
$PRAX Yikes. Sell the news event crushong all calls at the open. Will be lookomg for am entry on this one. Data was very strong.
0 · Reply
MaverikIT
MaverikIT Aug. 4 at 12:46 PM
$PRAX very nice $AXSM
0 · Reply
Latest News on PRAX
Praxis Precision Medicines to Host PRAX-628 Program Update

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines to Host PRAX-628 Program Update


Quantumup
Quantumup Aug. 20 at 2:03 PM
H.C. Wainwright reiterated $DRUG Buy/$85. LBPH - $HLUBF/ $HLBBF $PRAX $JAZZ UCBJY UCBJF SNDX AVXL PHVS H.C. Wainwright said in its note:
0 · Reply
R84877P
R84877P Aug. 11 at 1:43 PM
0 · Reply
Quantumup
Quantumup Aug. 11 at 12:51 PM
Piper Sandler reitd $PRAX OW/$270. Following positive Ph2 RADIANT FOS data, we hosted $PRAX for a fireside chat and learned new details reaffirming vormatrigine's competitive and potentially transformational product profile. Specifically, mgmt highlighted vormatrigine showed a consistent PK profile in refractory FOS (vs HVs) with a linear response across AUC and Cmax effectively derisking 40 mg may drive deeper efficacy. Additionally, mgmt specified most discontinuations occurred during weeks 1-3 of RADIANT where blinded Ph2/3 POWER1 data is showing substantially fewer discontinuations thus far. In that vein, mgmt detailed POWER1 is "at-least" 80% powered to show a placebo-adjusted 30% reduction in median seizure frequency where competitor data suggests consistent response across open-label and randomized placebo-controlled trials. Hence, we came away from the fireside chat even more confident in vormatrigine's value proposition with full RADIANT data and POWER1 completion 4Q25. $XENE $BHVN
1 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 10:30 AM
HC Wainwright & Co. updates rating for Praxis Precision Medicine ( $PRAX ) to Buy, target set at 105 → 115.
0 · Reply
LewisDaKat
LewisDaKat Aug. 5 at 12:55 AM
News out Praxis Precision Medicines to Participate in Upcoming Fireside Chat https://marketwirenews.com/news-releases/praxis-precision-medicines-to-participate-in-upcomin-5410024713418557.html $PRAX
0 · Reply
dgbio
dgbio Aug. 4 at 7:36 PM
$PRAX 22% of the patients with 100% seizure reduction is a very good result. Epilepsy is a diverse disease, with diverse treatments. You can't expect to treat everyone with a single drug. Novel treatments reach on average only about $300M in sales in the US market. If vormatrigine can treat 20% of the resistant FOS epilepsy patients it's more than $1 billion in the U.S. sales.
0 · Reply
R84877P
R84877P Aug. 4 at 5:05 PM
$PRAX Looking good
0 · Reply
Smellmahass
Smellmahass Aug. 4 at 1:39 PM
$PRAX News isnt good enough. I expect this to drop below 40 today.
3 · Reply
stingrae
stingrae Aug. 4 at 1:28 PM
$PRAX Yikes. Sell the news event crushong all calls at the open. Will be lookomg for am entry on this one. Data was very strong.
0 · Reply
MaverikIT
MaverikIT Aug. 4 at 12:46 PM
$PRAX very nice $AXSM
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 4 at 12:28 PM
$PRAX (+21.1% pre) Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine https://ooc.bz/l/72396
0 · Reply
Smellmahass
Smellmahass Aug. 4 at 12:12 PM
$PRAX I guess its a leak no official news yet. This needs to pop more than 30 percent atleast either way.
1 · Reply
Smellmahass
Smellmahass Aug. 3 at 6:14 PM
$PRAX This better move more than 20 percent tomorrow.
2 · Reply
dgbio
dgbio Aug. 1 at 5:48 PM
$PRAX One of the best stories in biotech right now. Disregard the tremor program. Three interesting molecules for epilepsy are advancing rapidly. A minor data release is scheduled for Monday before market open.
1 · Reply
Smellmahass
Smellmahass Aug. 1 at 6:40 AM
$PRAX No ones talking about this. What a surprise when theres catalysts on Monday thats deeemed important.
1 · Reply
Jmac9999
Jmac9999 Jul. 30 at 7:50 PM
$PRAX Where does this trade next week on +/- data?
1 · Reply
LarryFeelTheHeaton
LarryFeelTheHeaton Jul. 30 at 3:47 PM
$IXHL Blew Phase 2 out of the water: AHI down up to 83% — strong efficacy. Oral sleep apnea treatment = first of its kind. No serious side effects. OSA market = 900M patients globally. CPAP noncompliance = huge unmet need. 💰 Current market cap = ~$83M Meanwhile, look at comps: $ATXS (HAE, Ph2) = $250M $PRAX (CNS, Ph2) = $280M $ARDX (Ph2–3) = $400M+ $TGTX pre-run = $120M → ran 10x post-Ph3 📈 If IXHL starts Phase 3 w/ FDA blessing, re-rating to $200–300M cap is conservative 🔥 Float’s tight. Volume could detonate this.
2 · Reply
Smellmahass
Smellmahass Jul. 29 at 9:44 PM
$PRAX They will drop top line data on August 4?
0 · Reply
JarvisFlow
JarvisFlow Jul. 29 at 11:00 AM
Chardan Capital updates rating for Praxis Precision Medicine ( $PRAX ) to Buy, target set at 80.
0 · Reply
R84877P
R84877P Jul. 25 at 4:35 PM
0 · Reply
Quantumup
Quantumup Jul. 18 at 12:46 PM
H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine, for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG NBIX ( LBPH - HLBBF HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures, there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed vormatrigine's potential in FOS—we make that statement despite being "bulls" on the vormatrigine story. We believe the efficacy that relutrigine demonstrated in the EMBOLD study was potentially paradigm-shifting in its ability to offer seizure freedom to patients. H.C. Wainwright went on to say:
1 · Reply
Quantumup
Quantumup Jul. 16 at 10:02 AM
Citizens reiterated $RAPP Market Outperform-$28 after a KOL call reinforced its confidence in the pot'l for positive RAP-219 Phase 2 results in focal epilepsy. $PRAX $XENE $BHVN $NBIX TAK UCBJY Citizens said in its note: "We recently hosted Dr. Vikram Rao, a neurologist from UCSF and epilepsy KOL, for a discussion on the upcoming Phase 2 proof-of-concept results for RAP-219 in focal epilepsy. Dr. Rao is optimistic about the potential for RAP-219 in focal epilepsy due to its validated yet differentiated mechanism of action, compelling preclinical results, and innovative Phase 2 trial design. RAPP remains one of our two high-conviction calls into the Phase 2 results in September."
0 · Reply